South San Francisco has always had a knack for turning petri dishes into power plays, but Tahoe Therapeutics just raised the stakes. On August 8, 2025, the company locked in a $30 million Series A led by Amplify Partners, with Databricks Ventures, Wing Venture Capital, General Catalyst, Civilization Ventures, Conviction, Mubadala Capital Ventures, and AIX Ventures all stacking chips on the table. That puts the post-money valuation at $120 million and total funding at $42 million, solid fuel for a biotech that’s not here to dabble.
Founded in 2022, Tahoe Therapeutics started life as Vevo Therapeutics before a legal dust-up forced a rebrand this April. Different name, same ambition: build the world’s largest dataset for training AI models of human cells. The founding team is a murderers’ row of science and tech firepower, CEO and Co-Founder Nima Alidoust, Ph.D., with stints running Good Chemistry Company and shaping strategy at Rigetti Computing; CSO and Co-Founder Johnny Yu, Ph.D., whose UCSF work with Hani Goodarzi and Kevan Shokat birthed the Mosaic platform; Goodarzi himself, a UCSF Associate Professor and Core Investigator at Arc Institute; and Shokat, the HHMI Investigator and KRAS inhibitor pioneer who’s shaped modern cancer pharmacology.
Tahoe’s proprietary Mosaic platform doesn’t just collect data, it harvests drug-patient interaction maps at single cell resolution, across diverse patient populations, at a speed that makes industry norms look prehistoric. In February, they dropped Tahoe-100M, a dataset of 100 million cells and 60,000 drug-patient experiments, 50 times larger than all publicly available equivalents combined. Generated in two months, downloaded nearly 100,000 times, and open-sourced for global use, it’s already redefining what “scale” means in biotech AI.
This raise is about going bigger, ten times bigger. The goal: one billion single-cell datapoints, an AI training set that could turn drug discovery from a lottery into a precision strike. The capital will also push proprietary therapeutics toward the clinic, starting with cancer and branching out from there, while setting the stage for strategic partnerships with pharma and AI powerhouses.
Tahoe isn’t just playing in biotech’s sandbox, it’s building the beach. With the backing of this investor syndicate, the speed of Parse Biosciences’ GigaLab, the sequencing muscle of Ultima Genomics, and the data processing firepower of Databricks, they’re positioning themselves as the foundational data provider for the era of virtual cell models. The bet here is simple: in a world where better datasets mean better medicine, Tahoe Therapeutics intends to own the summit.
This one’s worth watching, not just for the science, but for the pace, precision, and nerve it takes to try and map the biology of humanity at the cellular level. That’s not a pivot. That’s a moonshot in a lab coat.
